- Odyssey Health, Inc. (ODYY), through its subsidiary Odyssey Medical Devices, Inc., has entered into a **Master Technology Sub-License Agreement** with NeuRX Health Inc. for exclusive, worldwide rights to the **BreastCheck® device**.  **[1626644_0001683168-25-007644_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-007644_odyssey_ex9901.htm:0]** **[1626644_0001683168-25-007644_odyssey_8k.htm:1]** 
- The BreastCheck® is a **non-invasive test for breast abnormalities** that is FDA registered in the United States and registered with regulatory authorities in the European Union and the United Kingdom.  **[1626644_0001683168-25-007644_odyssey_ex9901.htm:0]** 
- This agreement allows Odyssey Health to enter the **$26 billion breast cancer marketplace**, with the company expecting to begin commercialization and generate initial revenue soon.  **[1626644_0001683168-25-007644_odyssey_ex9901.htm:0]** 
- Consideration for the sub-license includes **cash payments** based on a percentage of net cash proceeds from equity line of credit draws, and **royalty payments** for each BreastCheck® unit sold.  **[1626644_0001683168-25-007644_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-007644_odyssey_ex1001.htm:1]**

Odyssey Health, Inc. Secures Exclusive Sub-License for BreastCheck® Device

- Odyssey Health, Inc. (OTCQB: ODYY) has signed a sub-licensing agreement for **exclusive, worldwide rights** to BreastCheck®, a non-invasive test for breast abnormalities.  **[1626644_f2017669eb1645aea8d5dbdc07c6c99b_0]** 
- BreastCheck® is a **home-use test** that provides immediate results in 15 minutes and is FDA registered in the United States, as well as registered with regulatory authorities in the EU and UK.  **[1626644_f2017669eb1645aea8d5dbdc07c6c99b_0]** 
- CEO Michael Redmond expects **commercialization and initial revenue** from BreastCheck® in the near future, marking the company's transition to a revenue-generating medtech company.  **[1626644_f2017669eb1645aea8d5dbdc07c6c99b_0]** 
- The breast cancer diagnostics market is currently valued in the **low tens of billions of dollars** and is projected to double or more over the next 8-10 years.  **[1626644_f2017669eb1645aea8d5dbdc07c6c99b_0]**

Odyssey Health Secures Worldwide Rights for BreastCheck®

- Odyssey Health, Inc. entered into a Promissory Note Agreement with Peter D'Arruda, effective **October 1, 2025**, receiving **$100,000**.  **[1626644_0001683168-25-007462_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-007462_odyssey_8k.htm:1]** 
- The Promissory Note is a **one-year note** with an **18% interest rate per annum**, and the full outstanding amount plus accrued interest is due by **September 30, 2026**.  **[1626644_0001683168-25-007462_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-007462_odyssey_8k.htm:1]** 
- In connection with the note, the company issued a warrant to Peter D'Arruda to purchase **100,000 shares of common stock** at an exercise price of **$0.10 per share**.  **[1626644_0001683168-25-007462_odyssey_ex1002.htm:0]** **[1626644_0001683168-25-007462_odyssey_8k.htm:1]** **[1626644_0001683168-25-007462_odyssey_ex1002.htm:1]**

Odyssey Health, Inc. Secures Promissory Note and Issues Warrants

- **Odyssey Health, Inc.** entered into a Securities Purchase Agreement with **Mast Hill Fund, L.P.** on **August 27, 2025**.  **[1626644_0001683168-25-006584_odyssey_ex1001.htm:0]** 
- The agreement includes the issuance of a **promissory note** with a principal amount of **$220,000.00**, an interest rate of **10% per annum**, and a **12-month maturity** from the issue date.  **[1626644_0001683168-25-006584_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-006584_odyssey_ex1002.htm:1]**  The note was purchased for **$198,000.00**.  **[1626644_0001683168-25-006584_odyssey_ex1002.htm:1]** 
- As additional consideration, **Odyssey Health, Inc.** issued **warrants** to purchase **1,000,000 shares** of common stock at an exercise price of **$0.10** per share, exercisable for **five years** from the issuance date.  **[1626644_0001683168-25-006584_odyssey_ex1001.htm:0]** **[1626644_0001683168-25-006584_odyssey_ex1003.htm:0]**

Odyssey Health (ODYY)